US 11,925,632 B2
Isoquinoline derivatives for use in treating GLUT1 deficiency syndrome
Pierre Magistretti, Crans-Montana (CH); Sylvain Lengacher, Lausanne (CH); Charles Finsterwald, Veyrier (CH); and Timothy John Ritchie, St Albans (GB)
Assigned to GLIAPHARM SA, Geneva (CH)
Appl. No. 17/790,148
Filed by GLIAPHARM SA, Geneva (CH)
PCT Filed Dec. 29, 2020, PCT No. PCT/EP2020/087950
§ 371(c)(1), (2) Date Jun. 30, 2022,
PCT Pub. No. WO2021/136763, PCT Pub. Date Jul. 8, 2021.
Claims priority of application No. 19220107 (EP), filed on Dec. 30, 2019.
Prior Publication US 2023/0102415 A1, Mar. 30, 2023
Int. Cl. A61K 31/47 (2006.01)
CPC A61K 31/47 (2013.01) 24 Claims
 
1. A method of treating Glucose transporter 1 deficiency syndrome (GLUT1-DS) in a subject, said method comprising administering in a subject in need thereof a therapeutically effective amount of a compound of Formula (I)

OG Complex Work Unit Chemistry
wherein R1, R2, R3, R4, R5 and R6 are independently selected from H, halogen, optionally substituted alkoxy, optionally substituted C1-C6 alkyl, optionally substituted amine, optionally substituted carboxylic acid or ester, nitro and nitrile; R7, R8, R9, R10 and R11 independently selected from H, halogen, optionally substituted alkoxy, optionally substituted C1-C6 alkyl, optionally substituted amine, optionally substituted carboxylic acid or ester, nitro and nitrile and a group of Formula (II): —(X)m—CR12R13R14 (II) wherein at least one group of R7, R8, R9, R10 and R11 is a group of Formula (II); X is selected from O, NR15, S, SO2, CH2 and hydrazine (—N—N—), m is an integer elected from 0 and 1 and R12, R13 and R14 are independently selected from H, OH, optionally substituted alkoxy, amide, pyrrolidone, nitrile, optionally substituted C1-C6 alkyl and halogen; Y is selected from —CR16R17— and —NR18—; R15 is selected from H, optionally substituted alkoxy and optionally substituted C1-C6 alkyl; R16 and R17 are independently selected from H, halogen, optionally substituted alkoxy, optionally substituted C1-C6 alkyl and optionally substituted aryl; R18 is independently selected from H or optionally substituted C1-C6 alkyl; pharmaceutically acceptable salts, hydrates, solvates or mixtures thereof.